At a glance
- Originator Institute of Materia Medica
- Developer Jiangsu Hengrui Medicine Co.
- Class Anti-inflammatories; Pyrroles; Small molecules; Sulfides
- Mechanism of Action Cyclo-oxygenase 2 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Osteoarthritis
- Clinical Phase Unknown Inflammation
Most Recent Events
- 22 Dec 2015 Jiangsu HengRui Medicine Co. initiates a phase I drug-drug interaction trial in Healthy volunteers in China (PO) (ChiCTR-OIB-15007606)
- 01 Jan 2015 Jiangsu HengRui Medicine Co. initiates enrolment in a phase I trial for Osteoarthritis in China (NCT02456688)
- 01 Jan 2015 Phase-I clinical trials in Osteoarthritis (In volunteers) in China (unspecified route) (NCT02426060)